1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals S.A.

MITPF
Mithra Pharmaceuticals S.A.US flagOther OTC
23.90
USD
+17.15
- -
1.60BMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
Revenue per Share
0.48
0.58
0.97
0.66
0.72
0.99
1.58
2.56
0.22
0.52
1.37
Basic EPS, GAAP
-0.02
-0.05
-0.15
-0.32
-1.13
-1.07
-0.34
-0.7
-2.25
-2.69
-1.22
Free Cash Flow per Basic Share
0.02
-0.01
-0.14
-0.95
-1.27
-1.44
-0.18
-1.65
-2.35
-2.26
-1.68
Dividend per Share
- -
0.02
0.11
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.07
0.08
-0.26
0.15
-0.96
-1.88
-2.03
-2.62
-4.6
-7.01
-7.24
Tangible Book Value per Share
- -
0.02
0.17
1.32
0.28
0.04
1.74
1.87
1.55
-1.76
-2.17
Basic Weighted Avg Shares
31
31
20
31
31
33
37
38
41
43
49
Sales/Revenue/Turnover
15
18
19
20
22
32
58
97
9
23
67
Operating Margin (%)
1.68
-3.16
-15.39
-69.82
-160.12
-80.51
24.51
26.99
-926.67
-387.67
-39.17
Depreciation Expense
1
1
1
1
1
2
3
6
10
10
12
Net Income, GAAP
-1
-2
-3
-10
-35
-35
-12
-27
-92
-117
-60
Effective Tax Rate (%)
1,240
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-4.25
-8.64
-15.52
-48.06
-156.16
-108.56
-21.36
-27.52
-1,019.78
-515.59
-88.99
Working Capital
- -
- -
- -
75
30
22
107
44
168
4
15
LT Debt
1
1
2
3
40
49
67
64
168
168
176
Total Equity
2
2
6
127
93
87
151
163
158
34
34
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-68.02
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
231.82%
-0.1%
-0.45%
Free Cash Flow
243.5%
160.86%
-15.81%
Net Income, GAAP
100.13%
54.96%
-48.99%
Sales/Revenue/Turnover
49.05%
80.44%
195.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
23
2022
- -
- -
- -
- -
67
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-2.69
2022
- -
- -
- -
- -
-1.22
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Christophe Marechal
Full Time Employees
270
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Rue Saint-Georges 5 Liège Belgium 4000
IPO Date
Feb 10, 2020
Website
mithra.com
Similar Companies
Kamada Ltd. (KMDA)
Love Hemp Group Plc (WRHLF)
MYUNGMOON Pharm co.,Ltd (017180.KS)
Asia Green Biotechnology Corp. (ASIA.CN)
Guobang Pharma Ltd. (605507.SS)
Cyclo Therapeutics, Inc. (CYTH)
Business
Mithra Pharmaceuticals S.A. (MITPF) develops, manufactures and markets innovative therapeutics focused on women's health, including contraception, menopause management and hormone-dependent cancers. The company offers Estelle, a combined oral contraceptive completed phase III trials; Donesta, an estetrol-based oral hormone treatment in phase III for menopause; Myring, a contraceptive vaginal ring; Tibelia, a tibolone-based tablet for hormone replacement therapy; Zoreline, a biodegradable implant for prostate, breast cancers and gynecological indications; and complex dosage forms such as polymeric products, sterile injectables and hormonal tablets. It operates through its CDMO platform providing early drug development to commercial manufacturing of vaginal rings, implants, liquid injectables and biologicals; targets pharmaceutical partners globally; and maintains subsidiaries in France, Germany, the Netherlands, Luxembourg and Brazil. Founded in 1999 and headquartered in Liège, Belgium, Mithra conducts research and production in Europe with international commercialization. In June 2024, Gedeon Richter acquires Neuralis SA, Estetra SRL and select Mithra R&D assets including estetrol platform rights for EUR 175 million to expand women's healthcare presence; Mithra files for bankruptcy proceedings amid the asset sale; secures additional Nexstellis patent protection in May 2024; enters exclusive negotiations for funding in May 2024; and postpones its annual general meeting in May 2024.